Eli Gilboa

Q: What Schools Are Affiliated With Eli Gilboa

Eli Gilboa is affiliated with the following schools: Weizmann Institute of Science, Icahn School of Medicine at Mount Sinai, Princeton University, University of Navarra, University of Miami, Duke University

Eli Gilboa's AcademicInfluence.com Rankings

Eli Gilboa

Biology

#9027

World Rank

#12183

Historical Rank

Immunology

#530

World Rank

#547

Historical Rank

biology Degrees

Download Badge

Biology

Eli Gilboa's Degrees

PhD Immunology Stanford University
Bachelors Biology University of California, Berkeley

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Eli Gilboa Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Eli Gilboa's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. (2005) (1021)
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras (2006) (945)
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo (1996) (923)
Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity (1990) (656)
DC-based cancer vaccines. (2007) (570)
Expression of a foreign gene in myeloid and lymphoid cells derived from multipotent haematopoietic precursors (1985) (552)
A detailed model of reverse transcription and tests of crucial aspects (1979) (550)
Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. (1986) (535)
Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. (2002) (534)
Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors (1997) (466)
Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. (1990) (457)
Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA (1998) (438)
The makings of a tumor rejection antigen. (1999) (432)
Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication (1990) (422)
Structure of the Abelson murine leukemia virus genome and the homologous cellular gene: Studies with cloned viral DNA (1980) (413)
Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes (1995) (398)
Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. (2003) (387)
Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. (2000) (372)
Classification of current anticancer immunotherapies (2014) (357)
Telomerase mRNA-Transfected Dendritic Cells Stimulate Antigen-Specific CD8+ and CD4+ T Cell Responses in Patients with Metastatic Prostate Cancer 1 (2005) (340)
Induction of antitumor immunity using bone marrow-generated dendritic cells. (1996) (340)
The determinants of tumour immunogenicity (2012) (339)
Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. (2000) (335)
Effect of internal viral sequences on the utility of retroviral vectors (1987) (325)
Cancer immunotherapy with mRNA‐transfected dendritic cells (2004) (322)
Immunotherapy of cancer with dendritic-cell-based vaccines (1998) (319)
Emerging clinical applications of RNA (2002) (302)
The promise of cancer vaccines (2004) (291)
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. (2008) (263)
Structure of a cloned circular Moloney murine leukemia virus DNA molecule containing an inverted segment: implications for retrovirus integration. (1980) (254)
Gene expression in mice after high efficiency retroviral-mediated gene transfer. (1985) (250)
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay (2010) (226)
Induction of Tumor-Specific Cytotoxic T Lymphocytes in Cancer Patients by Autologous Tumor RNA-Transfected Dendritic Cells (2002) (213)
Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA1 (2001) (207)
Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. (1994) (206)
Regression of tumors in mice vaccinated with professional antigen‐presenting cells pulsed with tumor extracts (1997) (199)
Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector. (1989) (195)
Induction of carcinoembryonic antigen (cea)‐specific cytotoxic t‐lymphocyte responses In vitro using autologous dendritic cells loaded with cea peptide or cea rna in patients with metastatic malignancies expressing cea (1999) (190)
Injection of Immature Dendritic Cells into Adjuvant-Treated Skin Obviates the Need for Ex Vivo Maturation 1 (2003) (182)
Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target (2018) (178)
Synergy between tumor immunotherapy and antiangiogenic therapy. (2003) (177)
Immunotherapy with Autologous, Human Dendritic Cells Transfected with Carcinoembryonic Antigen mRNA (2003) (175)
Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. (2003) (174)
Regression of bladder tumors in mice treated with interleukin 2 gene- modified tumor cells [published erratum appears in J Exp Med 1993 Jun 1;177(6):following 1831] (1993) (172)
Systemic Anti-CD25 Monoclonal Antibody Administration Safely Enhances Immunity in Murine Glioma without Eliminating Regulatory T Cells (2006) (159)
Human Dendritic Cells Transfected with RNA Encoding Prostate-Specific Antigen Stimulate Prostate-Specific CTL Responses In Vitro1 (2000) (159)
Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. (2008) (158)
Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells. (1993) (157)
CORRIGENDUM: Separable Bilayer Microfiltration Device for Viable Label-free Enrichment of Circulating Tumour Cells (2015) (156)
Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. (2007) (152)
The Human Vaccines Project: A roadmap for cancer vaccine development (2016) (151)
In vitro synthesis of a 9 kbp terminally redundant DNA carrying the infectivity of moloney murine leukemia virus (1979) (144)
Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. (2005) (144)
Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation (1991) (142)
An RNA toolbox for cancer immunotherapy (2018) (133)
Cell-free translation of simian virus 40 early messenger RNA coding for viral T-antigen. (1977) (133)
How tumors escape immune destruction and what we can do about it (1999) (129)
Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. (2005) (125)
Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. (2002) (125)
Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain (1994) (123)
Transfer and expression of cloned genes using retroviral vectors (1986) (122)
RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. (1995) (120)
Consensus nomenclature for CD8+ T cell phenotypes in cancer (2015) (118)
Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides. (1999) (117)
Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. (1997) (115)
An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. (1991) (112)
Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity. (2014) (109)
Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. (1994) (107)
Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen (2006) (105)
Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells (1998) (105)
Expression of genes introduced into cells by retroviral infection is more efficient than that of genes introduced into cells by DNA transfection (1984) (105)
Anti‐metastatic vaccination of tumor‐bearing mice with il‐2‐gene‐inserted tumor cells (1993) (104)
The risk of autoimmunity associated with tumor immunotherapy (2001) (102)
NFκB in Pancreatic Stellate Cells Reduces Infiltration of Tumors by Cytotoxic T Cells and Killing of Cancer Cells, via Up-regulation of CXCL12. (2018) (99)
Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. (1998) (99)
Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. (1992) (98)
Separable Bilayer Microfiltration Device for Viable Label-free Enrichment of Circulating Tumour Cells (2014) (98)
CD28 Aptamers as Powerful Immune Response Modulators (2013) (96)
Large scale analysis of the mutational landscape in HT-SELEX improves aptamer discovery (2015) (95)
The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer (2002) (92)
Antigen‐presenting cells pulsed with unfractionated tumor‐derived peptides are potent tumor vaccines (1997) (91)
Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. (1992) (91)
Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells. (1992) (88)
The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. (1994) (87)
Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. (2011) (86)
Gene therapy for infectious diseases: the AIDS model. (1994) (85)
Vaccination against Foxp3(+) regulatory T cells aggravates atherosclerosis. (2010) (84)
Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication (1990) (83)
Isolation and Optimization of Murine IL-10 Receptor Blocking Oligonucleotide Aptamers Using High-throughput Sequencing. (2012) (83)
Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. (1995) (79)
Targeting 4-1BB Costimulation to the Tumor Stroma with Bispecific Aptamer Conjugates Enhances the Therapeutic Index of Tumor Immunotherapy (2014) (76)
Phenotypic and Functional Maturation of Dendritic Cells Mediated by Heparan Sulfate1 (2000) (74)
Genome structure of Abelson murine leukemia virus variants: proviruses in fibroblasts and lymphoid cells (1981) (71)
Use of Oligonucleotide Aptamer Ligands to Modulate the Function of Immune Receptors (2013) (70)
Immunotherapy of cancer with genetically modified tumor vaccines. (1996) (69)
In utero gene transfer and expression: a sheep transplantation model. (1989) (69)
Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase. (1994) (68)
Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells. (1989) (67)
Induction of Human Dendritic Cell Maturation Using Transfection with RNA Encoding a Dominant Positive Toll-Like Receptor 41 (2004) (66)
Restoration of normal lysosomal function in mucopolysaccharidosis type VII cells by retroviral vector-mediated gene transfer. (1990) (64)
AptaCluster - A Method to Cluster HT-SELEX Aptamer Pools and Lessons from Its Application (2014) (63)
High-efficiency retroviral vector mediated gene transfer into human peripheral blood CD4+ T lymphocytes. (1996) (62)
Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. (2004) (62)
Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef. (2006) (61)
Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID. (1993) (59)
Comparison of the expression of a mutant dihydrofolate reductase under control of different internal promoters in retroviral vectors. (1992) (59)
Induction of CD4+ and CD8+ T-Cell Responses to the Human Stromal Antigen, Fibroblast Activation Protein: Implication for Cancer Immunotherapy (2005) (58)
Induction of Cytotoxic T Lymphocytes With Dendritic Cells Transfected With Human Papillomavirus E6 and E7 RNA: Implications for Cervical Cancer Immunotherapy (2000) (57)
Erratum: Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells (Journal of Experimental Medicine (April 1993) 177 (1127)) (1993) (56)
A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma. (1992) (56)
Mechanism of RNA primer removal by the RNase H activity of avian myeloblastosis virus reverse transcriptase (1984) (55)
Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction (1994) (55)
Role of intron-contained sequences in formation of moloney murine leukemia virus env mRNA (1984) (53)
Cell–surface markers for assessing gene transfer into human hematopoietic cells (1996) (50)
A hybrid DNA aptamer-dendrimer nanomaterial for targeted cell labeling. (2009) (50)
A frameshift mutation at the NH2 terminus of the nucleoprotein gene does not affect generation of cytotoxic T lymphocyte epitopes. (1991) (49)
Considerations for the use of cytokine-secreting tumor cell preparations for cancer treatment. (1995) (48)
Synthesis of a 600-nucleotide-long plus-strand DNA by virions of Moloney murine leukemia virus. (1979) (48)
Inhibition of human T-cell leukemia virus type I replication in primary human T cells that express antisense RNA (1989) (43)
Immunotherapy of cancer using cytokine gene-modified tumor vaccines. (1994) (43)
Inhibition of HIV-1 in CEM cells by a potent TAR decoy. (1995) (42)
Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity (2019) (41)
Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells. (1997) (39)
Aptamer-Targeted Attenuation of IL-2 Signaling in CD8+ T Cells Enhances Antitumor Immunity. (2017) (37)
Robust CD4+ and CD8+ T cell responses to SIV using mRNA‐transfected DC expressing autologous viral Ag (2007) (36)
A TIM-3 Oligonucleotide Aptamer Enhances T Cell Functions and Potentiates Tumor Immunity in Mice. (2017) (35)
Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T-cell responses and tumor immunity. (2003) (35)
Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. (2000) (33)
Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery (2015) (30)
Gene transfer into murine stem cells and mice using retroviral vectors. (1985) (30)
The cell-free translation of SV40 messenger RNA. (1975) (30)
Radiation-Induced Enhancement of Antitumor T-cell Immunity by VEGF-Targeted 4-1BB Costimulation. (2017) (30)
Isolation of embryonal carcinoma cell lines that express integrated recombinant genes flanked by the Moloney murine leukemia virus long terminal repeat. (1985) (30)
Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition (2012) (30)
Multiparameter-fluorescence activated cell sorting analysis of retroviral vector gene transfer into primitive umbilical cord blood cells. (1998) (28)
Purification and properties of human acrosin. (1973) (28)
A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma. (1992) (28)
Efficient retrovirus-mediated PIG-A gene transfer and stable restoration of GPI-anchored protein expression in cells with the PNH phenotype. (2001) (27)
Retroviral-mediated transfer of the human acid sphingomyelinase cDNA: correction of the metabolic defect in cultured Niemann-Pick disease cells. (1992) (27)
Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing. (2012) (27)
An experimental model simulating local recurrence and pelvic lymph node metastasis following orthotopic induction of prostate cancer (1994) (25)
Targeting 4-1BB Costimulation to Disseminated Tumor Lesions With Bi-specific Oligonucleotide Aptamers. (2011) (25)
Initiation of RNA synthesis in isolated nuclei. (1977) (24)
Preferential synthesis of viral late RNA by nuclei isolated from SV40 lytically infected cells (1976) (22)
Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction. (1994) (22)
Transient protection of human T-cells from human immunodeficiency virus type 1 infection by transduction with adeno-associated viral vectors which express RNA decoys. (1996) (20)
Retrovirus vectors and their uses in molecular biology (1986) (20)
Construction of a mammalian transducing vector from the genome of Moloney murine leukemia virus (1982) (19)
Purification of SV-40 messenger RNA by hybridization to SV-40 DNA covalently bound to Sepharose. (1975) (19)
Reducing toxicity of 4–1BB costimulation: targeting 4–1BB ligands to the tumor stroma with bi-specific aptamer conjugates (2015) (19)
Retroviral gene transfer of epidermal growth factor receptor into HL60 cells results in a partial block of retinoic acid-induced granulocytic differentiation. (1993) (16)
Multivalent 4-1 BB binding aptamers costimulate CD 8 + T cells and inhibit tumor growth in mice (2007) (16)
Influence of CD4 T cells and the source of major histocompatibility complex class II‐restricted peptides on cytotoxic T‐cell priming by dendritic cells (2002) (16)
Methylation and capping of RNA polymerase II primary transcripts by HeLa nuclear homogenates. (1978) (15)
Production of a discrete, infectious, double-stranded DNA by reverse transcription in virions of Moloney murine leukemia virus. (1979) (15)
Structure of cloned retroviral circular DNAs: implications for virus integration. (1981) (15)
4-1BB Aptamer-Based Immunomodulation Enhances the Therapeutic Index of Radiation Therapy in Murine Tumor Models. (2016) (14)
Cells treated with TAP-2 antisense oligonucleotides are potent antigen-presenting cells in vitro and in vivo. (1996) (14)
Retroviral gene transfer: applications to human therapy. (1988) (14)
Active immunization with tumor cells transduced by a novel AAV plasmid-based gene delivery system. (1997) (13)
Expression of new antigens on tumor cells by inhibiting nonsense-mediated mRNA decay (2013) (13)
Expression of functional epidermal growth factor receptors in a human hematopoietic cell line. (1991) (12)
Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity (2018) (11)
Retroviral gene transfer: applications to human therapy. (1990) (10)
Systemic Anti-CD 25 Monoclonal AntibodyAdministration Safely Enhances Immunity in Murine Gliomawithout Eliminating Regulatory TCells (2006) (10)
Significance of DNase I-hypersensitive sites in the long terminal repeats of a Moloney murine leukemia virus vector (1987) (9)
Gene therapy approaches in urologic oncology. (1995) (9)
Development of a lacZ marked WEHI-3B D+ murine leukemic cell line as an in-vivo model of acute non-lymphocytic leukemia. (1993) (9)
Metastatic Prostate Cancer T Cell Responses in Patients with + CD4 and + Cells Stimulate Antigen-Specific CD8 Telomerase mRNA-Transfected Dendritic (2005) (9)
Potentiating tumor immunity using aptamer-targeted RNAi to render CD8+ T cells resistant to TGFβ inhibition (2017) (8)
Knocking the SOCS1 off dendritic cells (2004) (8)
Induction of hematopoietic tumors using a viral construct containing c-myc cDNA from normal mouse spleen. (1986) (7)
Vaccination against Nonmutated Neoantigens Induced in Recurrent and Future Tumors (2020) (6)
Use of Retrovirus-Derived Vectors to Introduce and Express Genes in Mammalian Cells (1983) (5)
Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression (2016) (5)
Peptides Elicit CTL Responses Against Bound Peptide-Binding Activity and Can Calreticulin Displays In Vivo (1999) (4)
A clinically useful approach to enhance immunological memory and antitumor immunity (2014) (3)
A quantum leap in cancer vaccines? (2016) (3)
High level accumulation of an aberrantly spliced human DHFR RNA species. (1998) (3)
mRNA leapfrogs DNA to show promise for therapeutic gene transfer. (2012) (3)
83. Cell_Type Specific Delivery of siRNAs with Aptamer_siRNA Chimeras (2006) (3)
Aptamer-mediated transcriptional gene silencing of Foxp3 inhibits regulatory T cells and potentiates antitumor response (2021) (2)
Immune Modulatory Short Noncoding RNAs Targeting the Glioblastoma Microenvironment (2021) (2)
Erratum: Influence of CD4 T cells and the source of major histocompatibility complex class II-restricted peptides on cytotoxic T-cell priming by dendritic cells (Immunology (2002) 105 (47-55)) (2002) (2)
Retroviral Vector‐mediated Gene Transfer and Expression in Nonhuman Primates Following Autologous Bone Marrow Transplantation a (1987) (2)
Phase 1 trial of autologous dendritic cell vaccination with imiquimod immunomodulation in children and adults with refractory sarcoma. (2021) (1)
Dendritic cell-based cancer immunotherapy (2002) (1)
Transfected with Amplified Tumor RNA Cancer-Specific CTL Using Dendritic Cells Induction of Polyclonal Prostate (2013) (1)
Gene transfer into animals by retroviral vectors. (1986) (1)
The Makings of a Tumor Rejection Antigen Review (1999) (0)
Expression of new antigens on tumor cells by inhibiting nonsense-mediated mRNA decay (2013) (0)
Methods of treating malignancies and pathogenic infections using antigen-presenting cells loaded with RNA (1997) (0)
Abstract 4992: Development of a novel radiation-induced targeted immunotherapy strategy through oligonucleotide aptamer conjugation (2016) (0)
Author Correction: Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity (2021) (0)
Aptamer-targeted siRNA inhibition of raptor promotes the persistence of vaccine-induced CD8+ T cell responses and enhances protective immunity against influenza virus (IRM14P.452) (2015) (0)
Role of Stroma in Modulating Immune Checkpoint Blockade on T-Cells in Pancreatic Cancer (2019) (0)
Immunotherapy of Breast With Tumor RNA Transfected Dendritic Cell Vaccines (1999) (0)
Integrative RNA Biology Special Interest Group Meeting (2015) (0)
588. A central role of RNA in developing therapeutic vaccines for cancer and infectious diseases|[ast]| (2004) (0)
Abstract 1700: Radiation-induced vegf-targeted 4-1bb costimulation enhances immune control of tumor growth (2017) (0)
Induction of cytotoxic T lymphocytes (CTL) specific for HIV-1 or protection against tumor challenge by intranasal immunization with CTL peptide and cholera toxin (1996) (0)
Radiation-Induced Tumor Targeting of Immunomodulatory Aptamers Induces Abscopal Response and Tumor Control in Murine Models of Breast Cancer (2016) (0)
Therapeutic Vaccination with mRNA Transfected Dendritic Cells (2004) (0)
Dendritic cell based immunotherapy against adrenocortical carcinoma – screening for suitable targets (2006) (0)
Enhanced memory development in mice by aptamer targeted mTORC1 inhibition in CD8+ T cells (110.3) (2012) (0)
Immunotherapy of Metastatic Prostate Cancer Using Dendritic Cells Pulsed with Normal Prostate Tissue Antigens (2001) (0)
Abstract 2617: Inducing neoantigens in therapeutic and prophylactic cancer immunotherapy (2017) (0)
PeptidesCTL Responses Against Bound Peptide-Binding Activity and Can Calreticulin Displays In Vivo (2009) (0)
Cells Pulsed with R N A are Potent Ant igen-present ing Cells In Vitro and In Vivo (2003) (0)
Inhibition of HIV-1 with intracellular immunization with RNA decoys (1995) (0)
Abstract A023: Inducing neoantigens in disseminated tumor lesions to enhance their susceptibility to PD-1 blockade therapy (2016) (0)
Against Bound Peptides Activity and Can Elicit CTL Responses Calreticulin Displays In Vivo Peptide-Binding Wassenberg (1999) (0)
Abstract B68: Aptamer-targeted siRNA-mediated inhibition of mTORC1 in antigen-primed CD8+ cytotoxic T lymphocytes enhances immunological memory and antitumor immunity. (2013) (0)
Abstract B111: Vaccination against TAP downregulation-induced neoantigens to prevent future tumor development in the setting of recurrence or premalignancy (2019) (0)
Targeting immune evasion in cancer immunotherapy. (2006) (0)
Intracellular Immunization Against Hiv–a Novel Treatment Strategy For Aids (1993) (0)
Correction: Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells (European Journal of Immunology (1998) 28, 6 (1923-1933)) (1998) (0)
The Quest for mRNA Vaccines. (2022) (0)
Abstract 264: Vaccination against neoantigens induced in future tumors in the setting of recurrence and premalignancy (2018) (0)
Virus Synthesis of a 600-Nucleotide-Long Plus-Strand DNA by Virions of Moloney Murine Leukemia (0)
Receptor 4 Encoding a Dominant Positive Toll-Like Maturation Using Transfection with RNA Induction of Human Dendritic Cell (2004) (0)
Inhibition of HIV-1 with minimal Rev responsive element (RRE) decoys (1995) (0)
Proceedings: Purification and translation of mRNA coding for SV40 proteins. (1975) (0)
RNA aptamer against the IL-10 receptor block IL-10 function in vitro and in vivo (66.46) (2011) (0)
Abstract 1447: Capture, culture and characterization of viable circulating tumor cells in a syngeneic breast cancer mouse model system. (2013) (0)
Abstract A149: Assay development to validate RNAi candidates targeting FoxP3 transcription factor in adaptive regulatory T cell. (2013) (0)
Lymphokine Combination Vectors: A New Tool for Tumor Vaccination in Leukemias/Lymphomas (1992) (0)
Author Correction: Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity (2018) (0)
Abstract A25: Targeting costimulation to the tumor stroma with bispecific oligonucleotide aptamers. (2013) (0)
Abstract 4502: Cxcl-12-cxcr4 inhibition enhances immune response in pancreatic ductal adenocarcinoma (2018) (0)
Simultaneous downmodulation of mTORC1 and PD-1 in activated CD8 T-cells generates expanded population of exhaustion-resistant memory T-cells (IRM4P.495) (2014) (0)
Abstract B26: Prorapeutic vaccination against shared antigens induced in future tumors (2020) (0)
Abstract 3147: Generation of exhaustion-resistant memory CD8 T-cells by simultaneous downmodulation of mTORC1 and PD-1 in activated CD8 T-cells (2015) (0)
4-1BB Aptamer-Based Immunomodulation Enhances the Efficacy of Ionizing Radiation in a Preclinical Murine Tumor Model (2014) (0)
Abstract PR11: Potentiating immunological memory in mice using aptamer targeted siRNA delivery to inhibit mediators of effector differentiation in CD8+ cytotoxic T lymphocytes (2015) (0)
Human Renal Cancer Cells Retroviral Vector-mediated Lymphokine Gene Transfer into Updated Version (2006) (0)
Inverted Segment : Implications for Retrovirus Integration Structure of a Cloned Circular Moloney Murine Leukemia virus DNA Molecule Containing an Baltimore (0)
Intron sequences may influence the efficiency and correctness in selecting a 3'-splicing acceptor site. (1988) (0)
Secretion of SDF1/CXCL12 by Stromal Fibroblasts Shields Pancreatic Cancer from Immune Response (2018) (0)
Abstract 4702: Upgrading cancer immunotherapy: Checkpoint blockade mAb-ODN conjugate (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Eli Gilboa?

Eli Gilboa is affiliated with the following schools:

Eli Gilboa's Academic­Influence.com Rankings